The Year in Medicine 2008
In good times and bad, science doesn't sleep, and every year brings breakthroughs, setbacks, reasons for worry and reasons for joy. TIME's annual alphabetical roundup of a sampling of those stories gives you an overview of the year behind and a hint of what might be in the one ahead.
If one cholesterol-lowering drug is good, two must be better. That was the thinking behind Vytorin, a combination of Merck's Zocor and Schering-Plough's Zetia. Not so, it turns out. A study of 750 patients showed that while the combination did lower bad cholesterol, or LDL, it did little more to reduce the dangerous buildup of plaque than Zocor alone did — which costs far less than the combination drug Vytorin.
View the full list for "The Year in Medicine 2008"Special Features:
Around the Web
-
Anne Burrell Comes Out: Food Network Star Confirms She's A Lesbian
From THE HUFFINGTON POST
-
John Edwards Trial Juror Flirting With Ex-Senator
From THE HUFFINGTON POST
-
Tide Redesigning Box After Kids Mistake Detergent For Candy
From SLATE
-
Islamist Leader Likely To Face Former PM in Egyptian Runoff
From SLATE
